TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06037603

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain & Walk Exercise Every Day (BraW-Day)
Description: The Brain \& Walk Exercise Every Day (BraW-Day) program comprises 15-minute-long daily cognitive-walking tasks for 14 consecutive days. The program will be delivered on the Uplode mobile app. Each participant will be asked to perform three different 5-minute-long cognitive tasks (e.g., subtracting numbers or remembering long phrases) and one physical task (tandem walking or 8-shape walking) either indoors or outdoors at the same time for 15 minutes every day, which they will repeat daily for the next 13 days (2 weeks in total).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brain & Walk Exercise Every Day (BraW-Day)
Description: The Brain \& Walk Exercise Every Day (BraW-Day) program comprises 15-minute-long daily cognitive-walking tasks for 14 consecutive days. The program will be delivered on the Uplode mobile app. Each participant will be asked to perform three different 5-minute-long cognitive tasks (e.g., subtracting numbers or remembering long phrases) and one physical task (tandem walking or 8-shape walking) either indoors or outdoors at the same time for 15 minutes every day, which they will repeat daily for the next 13 days (2 weeks in total).
Study: NCT04982757

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagVenture MagPro System with Brainsight neuronavigation device
Description: 10x daily sessions of 1200 pulses of theta-burst stimulation lasting approximately ten minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MagVenture MagPro System with Brainsight neuronavigation device
Description: 10x daily sessions of 1200 pulses of theta-burst stimulation lasting approximately ten minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagVenture MagPro System with Brainsight neuronavigation device
Description: 10x daily sessions of 1200 pulses of theta-burst stimulation lasting approximately ten minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MagVenture MagPro System with Brainsight neuronavigation device
Description: 10x daily sessions of 1200 pulses of theta-burst stimulation lasting approximately ten minutes.
Study: NCT05512793

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard technique First colonoscopy without PolyDeep
Description: Standard technique First colonoscopy without PolyDeep

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Combination technique First colonoscopy with PolyDeep
Description: Combination technique First colonoscopy with PolyDeep
Study: NCT06335810

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Network Intervention
Description: Social Network interventions are an intentional effort to modify or use the characteristics of social networks to improve, generate, and maintain healthy behaviors among individuals and populations. This study will focus on implementing a behavioral social-network intervention to promote changes in weight loss behaviors.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Individual Lifestyle Intervention
Description: The individual lifestyle intervention will serve as the control group and will implement the use of DPP based health coaching sessions to promote individual level changes in weight loss behaviors.

Intervention type: OTHER
Group type: OTHER
Intervention: Social Network Member
Description: The social network member will serve as the friend, family member, or co-worker nominated to participate in the social network intervention by the social network intervention participant.
Study: NCT05768581

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concurrent Training
Description: Participants should perform strength training and aerobic exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength Training
Description: Participants should perform strength exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: Participants should perform aerobic exercises
Study: NCT06496763

Intervention type: DEVICE
Intervention: Vision-700
Description: OCT machines used for diagnostic purposes

Intervention type: DEVICE
Intervention: Vision-700
Description: OCT machines used for diagnostic purposes

Intervention type: DEVICE
Intervention: Vision-700
Description: OCT machines used for diagnostic purposes
Study: NCT05240209

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The researcher will give training to the training group about skin cancer, skin self-examination and sun protection behaviors.
Description: Materials used in education; Colorful brochures on the subject will be given to reinforce the slide show and post-training information.
Study: NCT06014437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLCL/Fg group
Description: Routine ulcerated wounds were cleaned, and the test group was given an equal-sized PLCL/Fg dressing to cover the wounds.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: Routine ulcerated wounds were cleaned and changed, and the control group was given an alginate dressing of equal size to cover the wounds
Study: NCT05103722

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined Aerobic and Resistance Exercise Training
Description: Participants receive personalized exercise plan for home-based two days of aerobic exercises (20-30-minutes) and two days of resistance exercises per week for 12 weeks. After completion of study intervention, participants will be assessed at the of study visit at Week 24.
Study: NCT05701202

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Super-Whey protein
Description: 2 different protein supplements (as above) will be given in a randomised crossover fashion to participants

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Isonitrogenous whey protein
Description: 2 different protein supplements (as above) will be given in a randomised crossover fashion to participants
Study: NCT04895111

Intervention type: DIAGNOSTIC_TEST
Intervention: Endobronchial ultrasound strain elastography
Description: Measurement of tissue elasticity of hilar and mediastinal lymph nodes through strain elastography measured during an endonbronchial ultrasound examination
Study: NCT04800653

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block
Description: Find the position of the stellate ganglion under ultrasound guidance, and inject 0.375% ropivacaine near the stellate ganglion to block the sympathetic nerves in the upper chest and head and neck
Study: NCT05198804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-c3
Description: ZN-c3 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-c3
Description: ZN-c3 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered.
Study: NCT05524688

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-glucan
Description: 2, 250 mg capsules of beta-glucan per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2, 250 mg capsules of cellulose
Study: NCT05969197

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Match Play Training
Description: 15 participants will be in Match play training group giving the Match play exercise protocol along with warm-up sessions for 6 weeks, measuring values before giving them protocol and after protocol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric Training
Description: 15 participants will be in Plyometric training group giving isotonic exercise protocol along with warm-up sessions for 6 weeks, measuring values before giving them protocol and after protocol.
Study: NCT06396520

Intervention type: OTHER
Intervention: No intervention, observational
Description: No intervention, observational

Intervention type: OTHER
Intervention: No intervention, observational
Description: No intervention, observational
Study: NCT05883176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Biosimilar QL 1101
Description: TACE + Bevacizumab (15mg/kg, intra-arterial infusion, Q3W) for 4 cycles, followed by maintenance therapy with Bevacizumab (15mg/kg, intravenously, Q3W) to a maximum total cycle of 18 unless any evidence of disease progression or unacceptable side effects.
Study: NCT05616208

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bioengineered Internal Anal Sphincter
Description: Autologous Bioengineered Internal Anal Sphincter
Study: NCT05345132

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine 20 Mg
Description: The initial dose of nifedipine will be 2 × 10 mg nifedipine capsules orally in the first hour, followed by 20 mg slow-release nifedipine every 6 hours for the next 47 hours. In the first hour after starting nifedipine, blood pressure and heart rate will be measured every 15 minutes. If blood pressure remains within the normal limits, treatment will be continued.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate
Description: Women will also receive MgSo4 as a loading dose of MgSo4 will be given immediately after enrollment as 4 gm diluted in 200 mL of saline solution administered intravenous over a period of 20 minutes. Afterwards, the maintenance dose of MgSo4 will be administered intravenous in a dose of 1 gm/hour given as 6 gm diluted in 500 mL saline solution titrated with a rate of 100 mL per hour, then this dose is repeated every 6 hours for 48 hours. Respiratory rate and knee jerk will be assessed hourly for women in the MgSo4 group. Serum magnesium level will be measured if clinically indicated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate
Description: Women will also receive MgSo4 as a loading dose of MgSo4 will be given immediately after enrollment as 4 gm diluted in 200 mL of saline solution administered intravenous over a period of 20 minutes. Afterwards, the maintenance dose of MgSo4 will be administered intravenous in a dose of 1 gm/hour given as 6 gm diluted in 500 mL saline solution titrated with a rate of 100 mL per hour, then this dose is repeated every 6 hours for 48 hours. Respiratory rate and knee jerk will be assessed hourly for women in the MgSo4 group. Serum magnesium level will be measured if clinically indicated.
Study: NCT05991271

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venus-Vitae Transcatheter Heart Valve System
Description: The Venus-Vitae THV is comprised of balloon-expandable and radiopaque cobalt-chromium alloy frame, porcine pericardium tri-leaflet, porcine pericardium inner skirt, polyurethane outer skirt, PTFE assembly sutures, and three radiopaque gold markers (Figure 1). The valve utilizes Venus Endura technology and stored in a non-aqueous condition.
Study: NCT04818372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM313-Dose escalation
Description: Subjects will receive a single dose of CM313 followed by a 3-week period for DLT observation. After that subjects will have 6 infusions at weekly intervals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM313
Description: Subjects will have 8 infusions at weekly intervals, and then 8 infusions at bi-weekly intervals. After that CM313 will be given every 4 weeks until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM313
Description: Subjects will have 8 infusions at weekly intervals, and then 8 infusions at bi-weekly intervals. After that CM313 will be given every 4 weeks until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: dexamethasone 40 mg/day at day 1,8,15,22 at 28 days cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: dexamethasone 40 mg/day at day 1,8,15,22 at 28 days cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25 mg/day lenalidomide 21 of 28 days cycle
Study: NCT05570669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (Macrogol 4000 52,500 g + Sodium sulphate anhydrous 3,750 g + Simethicone 0,080 g) full dose
Description: Taking the colonoscopy preparation drug (Clensia) in a single administration

Intervention type: DRUG
Group type: OTHER
Intervention: (Macrogol 4000 52,500 g + Sodium sulphate anhydrous 3,750 g + Simethicone 0,080 g) split dose
Description: Taking the colonoscopy preparation drug (Clensia) in two stages of administration
Study: NCT05120401

Intervention type: DEVICE
Intervention: presbyopia glasses
Description: fogging for glasses for far and intermediate

Intervention type: DEVICE
Intervention: presbyopia glasses
Description: fogging for glasses for far and intermediate
Study: NCT06490341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP Regimen, Nimotuzumab, Sintilimab
Description: gemcitabine,ciplatin, nimotuzumab, sintilimab
Study: NCT05897021

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive Writing on Minority Stressors
Description: The EWMS protocol will consist of 3 sessions delivered by a therapist (either in-person or remotely via telehealth platform) to sexual minority Veterans. The intervention will begin with an overview of the intervention, brief psychoeducation about expressive writing, and a review of the potential benefits of expressive writing. The initial session will also consist of psychoeducation on sexual minority stressors and common reactions to these stressors (i.e., universal stress reactions and minority-identity specific reactions) and how this relates to psychological outcomes, such as depression and anxiety, and high-risk behaviors, such as substance use and suicidal ideation. The initial session will be 60 minutes (introduction, psychoeducation, and first writing exercise) and the following two sessions (feedback, writing exercises, and check-ins) will take approximately 40 minutes.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Neutral Writing
Description: To be comparable to EWMS, the control intervention will also be a 3-session individual intervention involving engaging in a writing exercise per session. For the control writing exercises, participants will be asked to write for 30 minutes about their daily activities since waking up that day based on Pennebaker's standard writing paradigm (Pennebaker \& Beall, 1987). Individuals in the control condition will also be given information about the purpose of the writing exercises to be comparable to the psychoeducation information provided in EWMS. Similar to EWMS, the clinician will check in with the participant about the writing session, such as asking how the session went and how it felt to do the writing, following the 30 minutes of writing.
Study: NCT05520151

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ORAL IMPACT treatment
Description: the group of patients will be received a 7-days course of ORAL IMPACT

Intervention type: OTHER
Group type: OTHER
Intervention: control
Description: no intervention
Study: NCT06446245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: adjunctive doxycycline to standard anti-tuberculous treatment and corticosteroid therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti Tuberculosis Drug
Description: Standard anti-tuberculous therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anti Tuberculosis Drug
Description: Standard anti-tuberculous therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjunctive corticosteroid
Description: Adjunctive corticosteroids to be dosed at 0.4mg/kg/day of dexamethasone or equivalent for week 1, then 0.3mg/kg/day for week 2, 0.2mg/kg/day for week 3, 0.1mg/kg/day for week 4, then tapered to stop over the next 4 weeks. Other forms of corticosteroids are also acceptable eg. hydrocortisone, methylprednisolone at the equivalent dosage

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Adjunctive corticosteroid
Description: Adjunctive corticosteroids to be dosed at 0.4mg/kg/day of dexamethasone or equivalent for week 1, then 0.3mg/kg/day for week 2, 0.2mg/kg/day for week 3, 0.1mg/kg/day for week 4, then tapered to stop over the next 4 weeks. Other forms of corticosteroids are also acceptable eg. hydrocortisone, methylprednisolone at the equivalent dosage
Study: NCT05340894

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MCKENZIE exercises
Description: McKenzie method is popular amongst physiotherapists as a management approach for spinal pain and McKenzie exercises for LBP are beneficial treatment for increasing flexibility of spine and improving the pain with better results in pain relief

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: WILLIAM'S exercises
Description: William flexion exercise is to reduce pain or soreness and provide lower trunk stability by actively developing the abdominal muscles,gluteus maximus and hamstring, passively stretching the hip flexors and lower back muscles(sacro spinalis) and to restore or improve the work balance between the postural flexor and extensor muscle groups
Study: NCT05353400

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early urinary catheter removal
Description: Early catheter removal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Urinary catheter removal on POD 3
Description: Catheter removal on POD 3
Study: NCT04335942

Intervention type: OTHER
Group type: OTHER
Intervention: Alert AFNOR 3.6.
Description: This alert corresponds to the quantification of the percentage of weight on the slick distributed over a small area (55% on one to three zones totalling 30cm2),

Intervention type: OTHER
Group type: OTHER
Intervention: Alertes  AFNOR 3.6  et alertes  Guidelines .
Description: By alertes Guidelines we mean the clinical recommendations of the Spinal Cord medicine association, i.e. weight relief every 15 to 30 minutes over a period of 1 minute 51 for spinal cord injuries. For patients who do not push up, a tilt of at least 25° of seat and 120° of backrest or a minimum of 45° in one block.
Study: NCT05345535

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trampoline exercise
Description: 45 minutes of exercises that includes upper and lower extremity movements a trampoline with music

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking
Description: 45 minutes of moderate tempo walking
Study: NCT04957550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302 tablets、Placebo
Description: SHR0302 tablets dose 1 for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302 tablets、Placebo
Description: SHR0302 tablets dose 2 for 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SHR0302 tablets blank preparation for 24 weeks then SHR0302 tablets dose 1/dose 2 for 24 weeks
Study: NCT05223660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose KT07
Description: A single dose of 4 capsules, followed by multiple doses on Days 8-12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose KT07
Description: A single dose of 6 capsules, followed by multiple doses on Days 8-12

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Low dose Placebo
Description: A single dose of 4 capsules, followed by multiple doses on Days 8-12

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: High dose Placebo
Description: A single dose of 6 capsules, followed by multiple doses on Days 8-12
Study: NCT05998083

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: In addition to the individual support training program, the exercise group was given a balance and coordination exercise protocol including 40 minutes, 2 days a week.~These exercises are:~It consisted of warm-up (10 minutes), purposeful balance and coordination exercises (20 minutes), and cool-down (10 minutes) exercises.~Balance and coordination exercises with purpose were created with a series of exercises based on copying the shape of the blocks on the cards placed at the beginning of a track consisting of stations at the end of the track. The stations were composed of hopscotch station, tandem walking station in one line, bounce station, bucketing ping pong balls station and eight running stations.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: The control group continued only the individual support education program.
Study: NCT06190236

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stand-alone web-based cognitive behavioral therapy (CBT4CBT) for alcohol use disorder
Description: CBT4CBT is a 7-module web-delivered program based on CBT, an evidence-based behavioral treatment for alcohol use disorder (AUD).
Study: NCT05875051

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced-exertion high intensity training
Description: The intervention of the REHIT group will consist of three parts: i) 3 minutes of warm-up part at 50% of HRmax obtained in the effort test; ii) 3 min 20 sec to 3 min 40 sec of REHIT; and iii) 3 minutes of cool-down at 50% of HRmax obtained in the effort test. The REHIT part will consist of maximum cycling sprints of all-out exercise at 100% of the HRmax, increasing for up to 10 seconds, 15 seconds on week two and 20 seconds on week three. Then, 3 minutes of active rest at 50% of HRmax. Finally, 10 seconds of all-out exercise at 100% of the HRmax, rising to 15 seconds on week two and 20 seconds on week three.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Short moderate intensity training
Description: The SMIT group will receive a short moderate-intensity training with the same warm-up and cool-down exercises as the REHIT group. In addition, the main part of the session consisted of 6 minutes of moderate intensity exercise at 60-70% HRmax obtained in the effort test. In addition, the main part of the session increases 3 min every week as 6 min for the first 2 weeks, 9 min for the 3rd and 4th weeks, and 12 min for the last two weeks.